Insights & Research
Expert perspectives on AI, market access, clinical development, and the future of life sciences
Featured
AI in Drug Development: From Discovery to Approval
How artificial intelligence is compressing drug development timelines from 12 years to under 7, and what this means for patients and investors.
Market Access in 2026: The New Payer Landscape
Value-based contracting, outcomes-based agreements, and AI-driven payer negotiations are redefining how pharma companies maintain market access.
All Articles
Real-World Evidence: From Regulatory Acceptance to Competitive Advantage
7 min readFDA and EMA are increasingly accepting RWE for regulatory decisions. Here's how leading pharma companies are building RWE capabilities.
Precision Oncology: The Biomarker-Driven Revolution
9 min readBiomarker-driven therapy selection is transforming oncology outcomes. AI is accelerating biomarker identification and patient matching.
The AI Transformation of Pharmacovigilance
6 min readManual adverse event processing is giving way to AI-powered safety surveillance. Leading pharma companies are cutting costs by 70%.
Finding the Unfindable: AI and Rare Disease Patient Identification
7 min readWith patients scattered across millions of medical records, AI is solving the patient identification problem at scale.